Project: BG16RFPR001-1.003-0224-C01, procedure “Implementation of Innovations in Enterprises”
Main Objective: Introduction into production of an innovative product for the prevention and treatment of constipation
Beneficiary: Neopharm Bulgaria Ltd.
Total Value: BGN 1,777,777, of which BGN 799,999.65 is EU funding
Contract Duration: 15 months (ending on 16.03.2026)
Main Objective: Introduction into production of an innovative product for the prevention and treatment of constipation
Beneficiary: Neopharm Bulgaria Ltd.
Total Value: BGN 1,777,777, of which BGN 799,999.65 is EU funding
Contract Duration: 15 months (ending on 16.03.2026)
For more information, click HERE
Project: BG16RFOP002-1.005-0150, “Innovation and Development at Neopharm Bulgaria Ltd.”
Main Objective: Promotion of innovation and research activities at Neopharm Bulgaria Ltd.
Beneficiary: Neopharm Bulgaria Ltd.
Partner: Institute of Microbiology “Stefan Angelov” – Bulgarian Academy of Sciences
Total Value: BGN 436,038.00, of which BGN 320,514.70 is a grant, as follows: BGN 272,437.50 EU co-financing and BGN 48,077.20 national co-financing
Start: 16.11.2018
End: 16.11.2020
Main Objective: Promotion of innovation and research activities at Neopharm Bulgaria Ltd.
Beneficiary: Neopharm Bulgaria Ltd.
Partner: Institute of Microbiology “Stefan Angelov” – Bulgarian Academy of Sciences
Total Value: BGN 436,038.00, of which BGN 320,514.70 is a grant, as follows: BGN 272,437.50 EU co-financing and BGN 48,077.20 national co-financing
Start: 16.11.2018
End: 16.11.2020
Project: BG16RFOP002-2.077-0600
Main Objective: Support for medium-sized enterprises to overcome the economic consequences of the COVID-19 pandemic, ensuring working capital for Bulgarian medium-sized enterprises to cope with the impact of the COVID-19 crisis.
Beneficiary: Neopharm Bulgaria Ltd.
Total Value: BGN 150,000.00, of which BGN 127,500.00 EU co-financing and BGN 22,500.00 national co-financing
Start: 01.02.2021
End: 01.05.2021
Main Objective: Support for medium-sized enterprises to overcome the economic consequences of the COVID-19 pandemic, ensuring working capital for Bulgarian medium-sized enterprises to cope with the impact of the COVID-19 crisis.
Beneficiary: Neopharm Bulgaria Ltd.
Total Value: BGN 150,000.00, of which BGN 127,500.00 EU co-financing and BGN 22,500.00 national co-financing
Start: 01.02.2021
End: 01.05.2021
Project: Recovery of SMEs through Improving Energy Efficiency
Procedure: BG16RFOP002-6.002
Beneficiary: Neopharm Bulgaria Ltd.
Start: 16.09.2022
End: 16.03.2023
Total Value: BGN 287,500.00
Grant: BGN 143,750.00, representing 100% financing from the European Regional Development Fund under REACT-EU
Main Objective: Improving the company’s energy efficiency through the installation of new climate chambers
Procedure: BG16RFOP002-6.002
Beneficiary: Neopharm Bulgaria Ltd.
Start: 16.09.2022
End: 16.03.2023
Total Value: BGN 287,500.00
Grant: BGN 143,750.00, representing 100% financing from the European Regional Development Fund under REACT-EU
Main Objective: Improving the company’s energy efficiency through the installation of new climate chambers